Treatment-resistant depression: recent developments and future directions.
Mathew
Sanjay J
SJ
Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA. sanjay.mathew@mssm.edu
D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D046690:Deep Brain Stimulation; D003865:Major Depressive Disorder / Q000145:classification / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D004351:Drug Resistance; D004565:Electroconvulsive Therapy; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D015363:Quinolones / Q000627:therapeutic use; D013763:Tetrahydrofolates / Q000627:therapeutic use; D050781:Transcranial Magnetic Stimulation; D016896:Treatment Outcome; D055536:Vagus Nerve Stimulation
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D013763:Tetrahydrofolates; D000068180:Aripiprazole; C005984:5-methyltetrahydrofolate